Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Gliosarcoma × Immunotherapy, Adoptive × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Multiple Myeloma 2 Leukemia, Myeloid, Acute 2 Colorectal Neoplasms 2 Stomach Neoplasms 1 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Osteosarcoma 1 Neuroblastoma 1 Lymphoma, T-Cell 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Leukemia 1 Gliosarcoma 1 Glioblastoma 1 Esophageal Neoplasms 1 Cholangiocarcinoma 1 Central Nervous System Neoplasms 1 Burkitt Lymphoma 1 Brain Neoplasms 1

Interventions

Temozolomide 19 Radiotherapy 11 Bevacizumab 7 Radiation 4 Irinotecan 4 Erlotinib Hydrochloride 4 carmustine, poliferprosan 20 drug combination 3 Radiotherapy, Intensity-Modulated 3 O(6)-benzylguanine 3 Carmustine 3 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3 Radiotherapy, Conformal 2 Gadolinium DTPA 2 Filgrastim 2 Drug Therapy 2 Cilengitide 2 Chemotherapy, Adjuvant 2 Aminolevulinic Acid 2 vitespin 1 sargramostim 1 sapanisertib 1 poly ICLC 1 plerixafor 1 picropodophyllin 1 palbociclib 1 navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1 laromustine 1 imetelstat 1 gadobutrol 1 gadobenic acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02664363 2023-02-17

ExCeL

Duke University

Phase 1 Terminated

3 enrolled 8 charts

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡